TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05252416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-222
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-222
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-222
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-222
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Intra muscular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Intra muscular administration
Study: NCT06208306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab (SAR440340)
Description: Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itepekimab (SAR440340)
Description: Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
Study: NCT06137677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet Snack
Description: A sweet food will be served for the snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Savory Snack
Description: A savory food will be served for the snack
Study: NCT06116890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4951
Description: KHK4951 eye drop for 44 weeks until end of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4951
Description: KHK4951 eye drop for 44 weeks until end of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4951
Description: KHK4951 eye drop for 44 weeks until end of the trial
Study: NCT06598007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT3001
Description: CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT3001
Description: CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT3001
Description: CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT3001
Description: CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.
Study: NCT06116890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
Study: NCT06594406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: The dosing schedule of creatine administration is 3 g daily for the first week and then 5 g daily for the remaining 7 weeks and administration of bifidobacterium placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: The dosing schedule of creatine administration is 3 g daily for the first week and then 5 g daily for the remaining 7 weeks and administration of bifidobacterium placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Description: The dosing schedule of bifidobacterium administration is 1 billion colony forming unit (CFU) daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Description: The dosing schedule of bifidobacterium administration is 1 billion colony forming unit (CFU) daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium and creatine
Description: The dosing schedule of creatine administration is 3 g daily for the first week and then 5 g daily for the remaining 7 weeks. In parallel, the dosing schedule of bifidobacterium administration is 1 billion CFU daily for 8 weeks and administration of creatine placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium and creatine
Description: The dosing schedule of creatine administration is 3 g daily for the first week and then 5 g daily for the remaining 7 weeks. In parallel, the dosing schedule of bifidobacterium administration is 1 billion CFU daily for 8 weeks and administration of creatine placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of creatine placebo and bifidobacterium placebo for 8 weeks,

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of creatine placebo and bifidobacterium placebo for 8 weeks,
Study: NCT06666361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: The experimental group participates in the Mobio Health Multimedia Hypertension Promotion Program, which includes a hypertension education manual and a mobile health (m-health) intervention aimed at enhancing participants' health literacy and promoting healthy behaviors. In the first week, participants receive the health-education manual on-site, with face-to-face explanations and guidance on using mobile resources, such as text messaging, provided by the Sub-Investigator.~The mobile health intervention transforms the manual's content into six video units, each covering a specific topic, and these videos are continuously pushed over a two-month period. Distributed through LINE@, the official LINE account of the nursing platform, participants can easily access information via the chat menu at the bottom of the screen. This setup improves accessibility, making it convenient for participants to locate and use essential health information directly from the chat window.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: The control group received one copy of the same health education manual as the experimental group. The sub-Investigator only explained how to use the manual, and afterwards, no face-to-face teaching or m-Health interventions were conducted. After the experiment concluded, the m-Health program used by the experimental group would be provided to the control group.
Study: NCT06671067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote dielectric sensing system
Description: The remote dielectric sensing (ReDS) system is a non-invasive medical device that emits a low-power electromagnetic signal through the chest and lungs, which can accurately measure changes in lung fluid concentration.
Study: NCT06673186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overdenture
Description: Patient satisfaction (primary outcome) was measured by a visual analog scale (VAS). OHRQoL (secondary outcome) was measured by oral health impact profile (OHIP-14). Questions of VAS and OHIP-14 were evaluated after 3 months The patients were divided into two equal groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overdenture
Description: Patient satisfaction (primary outcome) was measured by a visual analog scale (VAS). OHRQoL (secondary outcome) was measured by oral health impact profile (OHIP-14). Questions of VAS and OHIP-14 were evaluated after 3 months The patients were divided into two equal groups.
Study: NCT06671613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FMD
Description: Plant-based diet program

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regular Diet Plus FMD
Description: Patients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Regular Diet Plus FMD
Description: Patients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6
Study: NCT06673303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic perceptual discrimination task
Description: The study featured two task conditions, each of which required the integration of information from both stimulus dimensions. In each condition, participants viewed a stimulus containing motion and color information and were required to specify one of two possible responses. Within each condition, rules and the response mapping changed occasionally, but always by changing on a fixed feature dimension (ie. rightward/purple, leftward/orange). These uncued intra-dimensional shifts involved translational shifts in the learning boundary, requiring them to adapt their decision making within a familiar dimension. These shifts compelled participants to continuously adjust their learning strategies by focusing on the most relevant feature dimension.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Participant brain imaging data will be collected concurrently while performing the perceptual discrimination task.
Study: NCT06672653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The monoterpenoid zinc tetra-ascorbo-camphorate (C14)
Description: The trial phase will consist of hospital administration by vaginal syringe of 5ml of 1% C14, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13). Gynaecological follow-up with HPV molecular testing and cervical smear will be performed two days after each course of treatment at S2, S6, S10, S14 and 2 weeks after the last course of treatment (S16). Unprotected sexual intercourse will not be permitted during each course of treatment, and for at least 72 hours before each genital swab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water group
Description: Instead of C14, distilled water will be administered in this group.
Study: NCT06672614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Exercise Hot Water Immersion
Description: Participants will cycle for 60 minutes at 50% of maximal oxygen uptake (VO2 max) followed by 30 minutes post-exercise hot water immersion (40oC) for 5 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants will cycle for 60 minutes at 50% maximal oxygen uptake (VO2 max) for 5 consecutive days. There is no water immersion following the exercise.
Study: NCT06671990

Intervention type: DRUG
Group type: OTHER
Intervention: Vericiguat
Description: Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
Study: NCT06671652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Duyugoda igalenisodi (Starting again the right way)
Description: Participants in the intervention arm will receive training and resources to build community resources and programming
Study: NCT06671158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Individual psychotherapy for weekly 12-sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Individual psychotherapy for weekly 12-sessions
Study: NCT06116890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol
Study: NCT04867317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants (n=172) will be randomized in a 1:1 ratio to rhGH (n=86) versus placebo (n=86) for six months, stratified by participating site. Both study participants and the study team will be blinded to treatment assignment. All participants will complete in-clinic follow-ups at Days 14, 40, 65, and 90 (3 months) and at day 180 (6 months). The primary outcome will be the mean difference in QoL-AGHDA scores between treatment arms at 6 months follow-up. Patients will discontinue the study intervention at 6 months, and will be followed-up two weeks subsequent, in order to assure patient safety and wellness, and to ensure maximal facilitation of patient transition back into routine care.
Study: NCT06671964

Intervention type: OTHER
Group type: OTHER
Intervention: Anthropometric measurements
Description: Anthropometric measurements of the students, including weight, height, muscle mass, fat quantity, and waist circumference, were measured. The WHO BMI charts were utilized for classification. Stratified Random selection

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: The collection of data was performed using the Atlas questionnaire (Al-Hazzaa et al., 2011) and nutrition knowledge and healthy lifestyle behavior questionnaire (Kalender et al., 2011) with additional questions related to self-efficacy and dietary practices adapted from the literature (Becher, 2009; Voss et al., 2017; Kowalski et al., 2004). Stratified Random selection
Study: NCT05924880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab 1500 mg as a 60-minute IV infusion in combination with gemcitabine-based chemotherapy Q3W. Upon completing chemotherapy, or discontinuing chemotherapy due to toxicity, durvalumab 1500 mg IV Q4W alone or in combination with gemcitabine.
Study: NCT05229822

Intervention type: DIAGNOSTIC_TEST
Intervention: LBP
Description: Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.

Intervention type: DIAGNOSTIC_TEST
Intervention: LBP
Description: Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.

Intervention type: DIAGNOSTIC_TEST
Intervention: LBP
Description: Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.

Intervention type: DIAGNOSTIC_TEST
Intervention: sCD14-ST
Description: Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.

Intervention type: DIAGNOSTIC_TEST
Intervention: sCD14-ST
Description: Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.

Intervention type: DIAGNOSTIC_TEST
Intervention: sCD14-ST
Description: Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.

Intervention type: DIAGNOSTIC_TEST
Intervention: 16s rRNA
Description: Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.

Intervention type: DIAGNOSTIC_TEST
Intervention: 16s rRNA
Description: Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.

Intervention type: DIAGNOSTIC_TEST
Intervention: 16s rRNA
Description: Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.
Study: NCT05464719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Given by IV
Study: NCT05810025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RealRisks
Description: RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
Study: NCT06671964

Intervention type: OTHER
Group type: OTHER
Intervention: Educational sessions
Description: The topics that covered included a healthy eating lifestyle, energy balance, food portion control, healthy snacking, the importance of physical activity and healthy eating, dietary practices, and nutrition-related self-efficacy.
Study: NCT06227325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48 combined with Sintilimab and XELOX
Description: RC48: 2.5 mg/kg, iv, d1, repeat every 2 weeks; Sintilimab: 200mg, iv, d1, repeat every 3 weeks; XELOX: Oxaliplatin 130mg/m2, iv, d1；Capecitabine1000 mg po, bid, d1-14, repeat every 3 weeks
Study: NCT06671964

Intervention type: OTHER
Group type: OTHER
Intervention: Educational sessions
Description: The topics that covered included a healthy eating lifestyle, energy balance, food portion control, healthy snacking, the importance of physical activity and healthy eating, dietary practices, and nutrition-related self-efficacy.

Intervention type: OTHER
Group type: OTHER
Intervention: Educational sessions
Description: The topics that covered included a healthy eating lifestyle, energy balance, food portion control, healthy snacking, the importance of physical activity and healthy eating, dietary practices, and nutrition-related self-efficacy.
Study: NCT06672354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: 1- Otago Exercise Program: i) This exercise program will consist of strengthening, balance exercises and walking plan. The OEP will be performed according to the following: 5 min warm-up, 10 min resistance training and 15 min balance exercises.~ii) The strength training protocol targets, on hip abductors, knee flexors, knee extensors, plantarflexors, and dorsiflexors.All exercises will be performed for 10 repetitions. This protocol recommends strength training 3 days per week.~iii) The balance retraining protocol incorporates various exercises. The exercises progress in difficulty through four levels, with Level 1 being the easiest and Level 4 the most challenging. Balance exercises will progress from holding onto a stable supporting structure such as heavy furniture to perform the exercises independent of the support. The protocol recommends participants to carry out balance exercises 3 days a week.~iv) Participants will be instructed to walk at their usual pace for 30 minutes, twice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Immersive Virtual Reality Training
Description: In this interventional group, VR training exercises will be performed by using Xbox Kinect, which includes a Kinect sensor.-The monitor or Tv screen will recognize the movements of participants via camera and infra-red motion sensors.-In order to perform simulated exercises in each session, the participant will be positioned at 1.5-2 meter from the monitor or TV screen.-The virtual reality training exercises will include Kinect Adventure games (Rally Ball, 20,000 leaks, Reflex Ridge) and Sports pack 1 games (Super Saver, Target Kick, Body ball).-Exercises will be continued for 30-45 minutes each session, for 3 alternate days per week for a total period of 12 weeks.
Study: NCT05295615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECHS AD Device
Description: Pulsed electromagnetic therapy device
Study: NCT06311175

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Tracking Prescription
Description: Dietary tracking prescriptions to follow during a digital weight loss intervention.
Study: NCT06013800

Intervention type: OTHER
Intervention: Measurement of sodium levels
Description: Patients will get measurements of sodium levels daily in the first 48 hours, then daily or every other day until normal sodium levels (\>135mEq/L).

Intervention type: OTHER
Intervention: Measurement of sodium levels
Description: Patients will get measurements of sodium levels daily in the first 48 hours, then daily or every other day until normal sodium levels (\>135mEq/L).
Study: NCT05075655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound guided miniforceps biopsy and transbronchial needle aspiration
Description: Mediastinal node is sampled using three path of classic ultrasound guided transbronchial needle aspiration (EBUS-TBNA).~A reduce size forceps is then inserted inside the mediastinal node via the duc EBUS-TBNA made and biopsies (EBUS-MFB) are made using real time ultrasound guidance.
Study: NCT05633979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat
Description: Given by PO
Study: NCT06204029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyone can sing
Description: The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means.